P688: ASC2ESCALATE: A US PHASE 2, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND-LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)

ABSTRACT:

SUBMITTER: Atallah E 

PROVIDER: S-EPMC10428989 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature